CS Diagnostics Corp. (CSDX)
| Market Cap | 10.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -341.61K |
| Shares Out | 137.34M |
| EPS (ttm) | -3.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,762 |
| Average Volume | 134,172 |
| Open | 0.0980 |
| Previous Close | 0.1000 |
| Day's Range | 0.0648 - 0.0980 |
| 52-Week Range | 0.0500 - 5.6400 |
| Beta | -20.31 |
| RSI | 36.87 |
| Earnings Date | n/a |
About CS Diagnostics
CS Diagnostics Corp. manufactures and sells medical products for medicine, radiology, cardiology, and radiation therapy in Germany and internationally. The company offers injectors, pistons, hose systems, PCR tests, medicines, and gloves. It also operates as a pharmaceutical wholesaler. The company was formerly known as FlashZero Corp. and changed its name to CS Diagnostics Corp. in August 2023. The company was incorporated in 1996 and is based in Neuss, Germany. [Read more]
Financial Performance
Financial StatementsNews
CS Diagnostics Corp. is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS
CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and i...
OTCQB-CSDX Appoints Lachman Consultants for CS-Protect Hydrogel FDA Approval
CS DIAGNOSTICS CORP. ANNOUNCES THE APPOINTMENT OF FDA CONSULTANTS Innovative tissue spacer technology for cancer radiology treatments CHEYENNE, WY / ACCESS Newswire / March 12, 2025 / CS Diagnostics C...
CS Diagnostics Corp. Announces U.S. Launch of MEDUSA
NEUSS, Germany--(BUSINESS WIRE)--CS Diagnostics Corp. Announces U.S. Launch of MEDUSA.